MedTrace Logo

AVANTI - Avelox® in Acute Exacerbations of chroNic bronchiTIs

NCT00846911 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2672

Last updated 2012-07-09

No results posted yet for this study

Summary

The objective of this global non-interventional study is to evaluate the impact of Acute Exacerbation of Chronic Bronchitis(AECB) on the patient and the community as well as the safety and effect of a treatment with Moxifloxacin tablets in daily life clinical practice. This includes data on the course of symptom relief, speed of return to normal daily life activities as well as records on adverse events.

This study will be performed in accordance with international guidelines like EMEA (EMEA, EUDRALEX Volume 9A, Pharmacovigilance for Medicinal Products for Human Use) as well as local laws.

Conditions

  • Bronchitis, Chronic

Interventions

DRUG

Moxifloxacin (Avelox, BAY12-8039)

Patients with acute exacerbation of chronic bronchitis for whom the physician decided to prescribe moxifloxacin

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2010-04-30
Completion
2010-04-30

Countries

  • Albania
  • Bosnia and Herzegovina
  • Kazakhstan
  • Moldova
  • North Macedonia
  • Russia
  • Slovakia
  • Ukraine

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00846911 on ClinicalTrials.gov